Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Myriad Genetics Banks on Product Launches, Competition Rife

2018-02-19 zacks
On Feb 16, we issued an updated research report on Myriad Genetics, Inc. (MYGN - Free Report) . The stock carries a Zacks Rank #3 (Hold). (37-0)

Cancer data: a dive into the depths - European Biotechnology

2018-02-16 european-biotechnology
As Big Data analytics begin to inspire medical decisionmaking, companies and scientists have gone to war over access to data derived from patient biopsies. Cancer profiling is a seminal situation. While some companies are seeking to profit from approaches to advanced mutation analysis, researchers are vociferous in demanding open access to proprietary data­bases behind company firewalls. (9-0)

MYGN / Myriad Genetics, Inc. / STATE STREET CORP - MYRIAD GENETICS, INC. (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING MYRIAD GENETICS, INC. (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 62855J104 (CUSIP NUMBER) 12/31/2017 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHA

MYGN / Myriad Genetics, Inc. / STATE STREET CORP - MYRIAD GENETICS, INC. (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING MYRIAD GENETICS, INC. (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 62855J104 (CUSIP NUMBER) 12/31/2017 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHA

MYGN / Myriad Genetics, Inc. / D. E. SHAW & CO, L.P. - SC 13G/A (Passive Investment)

2018-02-16 sec.gov
      SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549   SCHEDULE 13G (Amendment No. 1)     Under the Securities Exchange Act of 1934     Myriad Genetics, Inc. (Name of Issuer)     Common Stock, $0.01 par value (Title of Class of Securities)     62855J104 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the following box to designate the rule pursuant to which the Schedule is filed:   ¨ Rule 13d-1(b) x Rule 13d-1(c) ¨ Rule 13d-1(d)  

MYGN / Myriad Genetics, Inc. / D. E. SHAW & CO, L.P. - SC 13G/A (Passive Investment)

2018-02-15 sec.gov
      SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549   SCHEDULE 13G (Amendment No. 1)     Under the Securities Exchange Act of 1934     Myriad Genetics, Inc. (Name of Issuer)     Common Stock, $0.01 par value (Title of Class of Securities)     62855J104 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the following box to designate the rule pursuant to which the Schedule is filed:   ¨ Rule 13d-1(b) x Rule 13d-1(c) ¨ Rule 13d-1(d)  

MYGN / Myriad Genetics, Inc. / Camber Capital Management LLC - PRIMARY DOCUMENT (Passive Investment)

2018-02-14 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 2)   Myriad Genetics, Inc. (Name of Issuer)   Common Stock, par value $0.01 per share (Title of Class of Securities)   62855J104 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒  Rule 13d-1(c) ☐

MYGN / Myriad Genetics, Inc. / Camber Capital Management LLC - PRIMARY DOCUMENT (Passive Investment)

2018-02-14 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 2)   Myriad Genetics, Inc. (Name of Issuer)   Common Stock, par value $0.01 per share (Title of Class of Securities)   62855J104 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒  Rule 13d-1(c) ☐

Myriad Genetics' Positive Study Data May Expand Customer Base

2018-02-13 zacks
Myriad Genetics, Inc. (MYGN - Free Report) has been dominating the headlines on favorable results from a large study of the myRisk Hereditary Cancer test. Notably, the results were featured during the poster presentation at the 2018 Genitourinary Cancer Symposium in San Francisco, CA. (12-0)

MYGN / Myriad Genetics, Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G (Passive Investment)

2018-02-09 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No.   )*       MYRIAD GENETICS INC (Name of Issuer)   Common Stock (Title of Class of Securities)     62855J104                                 (CUSIP Number)                                   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule

MYGN / Myriad Genetics, Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G (Passive Investment)

2018-02-09 sec.gov
      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No.   )*       MYRIAD GENETICS INC (Name of Issuer)   Common Stock (Title of Class of Securities)     62855J104                                 (CUSIP Number)                                   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule

Myriad Genetics: Analyzing The Qualms Over The Multiple

2018-02-09 seekingalpha
In late January, it was suggested the market's multiple for Myriad Genetics (at 30) was too high. Most investors would agree market multiples should be justifiable. (2-0)

MYGN / Myriad Genetics, Inc. S-8 2017 EQUITY INCENTIVE PLAN

2018-02-07 sec.gov
mygn-s8.htm   As filed with the Securities and Exchange Commission on February 7, 2018   REGISTRATION NO. 333 ‑     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM S‑8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933   MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter)   Delaware 87-0494517 (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.

MYGN / Myriad Genetics, Inc. 10-Q - QUARTER ENDED 12/31/17 (Quarterly Report)

2018-02-07 sec.gov
mygn-10q_20171231.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-Q   (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from            to            Commission file number:  0-26642   MYRIAD GENETICS, INC.

Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q2

2018-02-07 zacks
Myriad Genetics, Inc. (MYGN - Free Report) reported adjusted earnings per share (EPS) of 31 cents in the second quarter of fiscal 2018, up 19.2% year over year. Moreover, adjusted EPS beat the Zacks Consensus Estimate by a solid margin of 29.2% and exceeded the company’s guided range of 22-24 cents. (8-0)


CUSIP: 62855J104